Fiasp

DRUG6 trials

Sponsors

Stanford University, Arecor Limited, McGill University, University of Ljubljana, Faculty of Medicine, McGill University Health Centre/Research Institute of the McGill University Health Centre

Conditions

Diabetes Mellitus, Type 1Hyperglycemia, PostprandialType 1 DiabetesType 1 Diabetes Mellitus

Phase 1

AT247, NovoRapid® and Fiasp® in Glucose Clamp Study

CompletedNCT03959514

Arecor LimitedDiabetes Mellitus, Type 1

Start: 2019-04-12End: 2019-08-08Updated: 2019-09-30

AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study

CompletedNCT05184868

Arecor LimitedDiabetes Mellitus, Type 1

Start: 2022-01-03End: 2022-09-09Updated: 2022-09-13

Phase 4

Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy

CompletedNCT03554486

Stanford UniversityDiabetes Mellitus, Type 1

Start: 2018-07-23End: 2019-03-30Updated: 2021-08-18

Unknown Phase

Alleviating Carbohydrate Counting for Patients With Type 1 Diabetes Using a Novel Insulin-plus-pramlintide Artificial Pancreas

CompletedNCT04163874

McGill UniversityHyperglycemia, Postprandial, Type 1 Diabetes, Type 1 Diabetes Mellitus

Start: 2020-02-14End: 2022-01-30Updated: 2022-10-10

Fast Advanced Closed-Loop Therapy

CompletedNCT04853030

University of Ljubljana, Faculty of MedicineType 1 Diabetes

Start: 2021-04-06End: 2021-09-20Updated: 2021-10-01

A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes

CompletedNCT05199714

McGill University Health Centre/Research Institute of the McGill University Health CentreType 1 Diabetes

Start: 2022-02-21End: 2023-03-25Updated: 2023-10-25

Related Papers

Simple meal announcements and pramlintide delivery versus carbohydrate counting in type 1 diabetes with automated fast-acting insulin aspart delivery: a randomised crossover trial in Montreal, Canada.

2024-07-018 citations

A Comparison of Faster Insulin Aspart with Standard Insulin Aspart Using Hybrid Automated Insulin Delivery System in Active Children and Adolescents with Type 1 Diabetes: A Randomized Double-Blind Crossover Trial

Diabetes Technology & Therapeutics2023-07-0528 citations